Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 17/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 16/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TESK1 | Q15569 | 2/20 | 0.33 |
| ▸ | TESK2 | Q96S53 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018434 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4019003 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4017708 | 0.89 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| Hydrochloric Acid SCHEMBL4017653 | 0.78 | HRH3 (0.38) | LIMK1MAPK14 | |
| SCHEMBL15626293 | 0.78 | LIMK1 (0.36) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL16989331 | 0.78 | LIMK1 (0.36) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL13870027 | 0.78 | LIMK1 (0.36) | LIMK1LIMK2MAPK14 | |
| SCHEMBL4017724 | 0.78 | LIMK1 (0.38) | LIMK1LIMK2MAPK14TESK1TESK2 | |
| SCHEMBL4016503 | 0.77 | HRH3 (0.39) | LIMK1MAPK14 | |
| SCHEMBL4017130 | 0.77 | HRH3 (0.39) | LIMK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663241-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030216-A1 | 5-ARYLPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |